Tejnaksh Healthcare Sees Adjustment in Evaluation Amid Technical and Financial Trends

Tejnaksh Healthcare operates within the Hospital & Healthcare Services industry, with a market capitalisation grade of 4. The stock closed at ₹16.50 on the trigger date, 19 Nov 2025, marking a day change of -1.61% from the previous close of ₹16.77. The 52-week price range spans from ₹16.20 to ₹29.50, indicating a significant contraction in price over the past year.

One of the primary drivers behind the adjustment in evaluation is the shift in technical trends. The technical grade transitioned from mildly bearish to bearish, signalling a more cautious outlook based on chart patterns and momentum indicators. Weekly and monthly technical summaries reveal a mixed picture: the Moving Average Convergence Divergence (MACD) indicator is bearish on a weekly basis but mildly bullish monthly, while the Relative Strength Index (RSI) shows bullish signals weekly but no clear trend monthly. Bollinger Bands indicate bearish trends on both weekly and monthly timeframes, and daily moving averages remain bearish. The Know Sure Thing (KST) indicator is mildly bullish weekly but bearish monthly, and Dow Theory assessments suggest a mildly bearish weekly trend with no definitive monthly trend. These technical signals collectively suggest increased selling pressure and subdued momentum in the near term.

From a financial trend perspective, Tejnaksh Healthcare’s recent quarterly performance for Q2 FY25-26 has been largely flat, with operating cash flow for the year recorded at a low ₹0.38 crore. The company’s net sales have exhibited a compound annual growth rate (CAGR) of -1.19% over the last five years, indicating stagnation or slight contraction in revenue generation. Return on Equity (ROE) averaged 9.52% over the same period, reflecting modest profitability relative to shareholders’ funds. These figures underscore challenges in generating robust financial growth and returns.

Examining the stock’s returns relative to the benchmark Sensex reveals consistent underperformance. Over the past week, the stock returned -3.79% compared to the Sensex’s 0.96%. This trend extends across longer horizons: one month (-4.40% vs 0.86%), year-to-date (-26.70% vs 8.36%), one year (-27.73% vs 9.48%), three years (-71.83% vs 37.31%), five years (-15.38% vs 91.65%), and ten years (-55.10% vs 232.28%). Such persistent lagging against the benchmark highlights structural challenges in the company’s market performance.

Despite these headwinds, valuation metrics present a contrasting view. Tejnaksh Healthcare’s ROE of 6.3% paired with a price-to-book value of 1.3 suggests a valuation that is attractive relative to its peers. The stock is trading at a discount compared to the average historical valuations within its sector, potentially offering value for investors seeking exposure to healthcare services at a lower price point. However, this valuation attractiveness is tempered by the company’s declining profits, which have fallen by approximately 25.7% over the past year, aligning with the negative return profile.

Quality parameters also factor into the adjustment in evaluation. The company’s long-term fundamental strength is characterised as weak, with flat financial results and low profitability metrics. The majority shareholding remains with promoters, which may influence governance and strategic direction. The combination of subdued financial growth, modest profitability, and technical bearishness has contributed to the revision in the company’s overall score grade.

In summary, the adjustment in Tejnaksh Healthcare’s evaluation reflects a confluence of factors across four key parameters. The technical outlook has shifted towards a more bearish stance, supported by multiple momentum and trend indicators. Financial trends reveal flat quarterly performance, low operating cash flow, and a negative sales growth trajectory over five years. Valuation metrics indicate the stock trades at a discount relative to peers, though this is accompanied by declining profitability. Quality considerations highlight weak long-term fundamentals and modest returns on equity. Together, these elements have informed the recent revision in the company’s score grade as of 19 Nov 2025.

Investors analysing Tejnaksh Healthcare should weigh these factors carefully, considering the persistent underperformance against benchmarks and the mixed signals from valuation and technical indicators. The healthcare services sector remains competitive, and the company’s ability to reverse current trends will be critical for future evaluation adjustments.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →